Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92
Published . Updated .
The average one-year price target for Jasper Therapeutics (NASDAQCM:JSPR) has been revised to $8.92 / share. This is an increase of 19.86% from the prior estimate of $7.45 dated September 11, 2026. These figures represent aggregate analyst targets compiled from multiple sources
Directly affected
- JSPR Jasper Therapeutics
Named in this report.
Indirectly affected
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Jasper Therapeutics (NASDAQCM:JSPR) has been revised to $8.92 / share. This is an increase of 19.86% from the prior estimate of $7.45 dated September 11, 2026. These figures represent aggregate analyst…
Source: Nasdaq Markets
How far Jasper Therapeutics (JSPR) has moved since 2 Oct 2026
Since the first closing price after “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92,” Jasper Therapeutics (JSPR) is -18.82%. The S&P 500 fund (SPY) is -1.08% over the same days, a -17.74% difference versus the market.
Who gains and who loses around Jasper Therapeutics (JSPR)
Companies mentioned with this story
- JSPR Jasper Therapeutics
Jasper Therapeutics (JSPR) is linked, with no stored direction, high confidence in the 2 Oct 2026 story “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92.” Reason on file: The reported development directly names JASPER THERAPEUTICS INC in the headline; GA resolved that company to JSPR
- FGSI Ft Vest Growth Strength & Target Income Etf
For “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92,” Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence. Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
For “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92,” Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92.” Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
In “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92,” Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92.” Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
In “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92,” Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence. Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Jasper Therapeutics (JSPR)
Jasper Therapeutics (JSPR) is the company in “Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92,” the 2 Oct 2026 this story story.
The link for Jasper Therapeutics (JSPR) is this: The reported development directly names JASPER THERAPEUTICS INC in the headline; GA resolved that company to JSPR
Ft Vest Growth Strength & Target Income Etf (FGSI) is here too. Its reason reads: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Jasper Therapeutics (JSPR) price range
FGSI traded between 20.20 and 20.62 across 5 sessions. The latest close on file is 20.27. ITDB traded between 34.52 and 35.29 across 15 sessions. The latest close on file is 35.02. JSPR traded between 0.46 and 0.61 across 12 sessions. The latest close on file is 0.48.
How strong the case is around Jasper Therapeutics (JSPR)
46 out of 100
“Jasper Therapeutics Consensus Price Target Increased 19.86% to $8.92” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.